Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B

Table 4 Lamivudine resistance mutations and HBV genotypes in patients with a virological breakthrough or primary non-response

Patients	Genotype	Baseline	Mutation (mo)
Breakthrough
11	D	Wt	rtM204V (11)
12	D	Wt	None (19)
23	D	Wt	rtM204V (24)
14	A	Wt	rtM204V
			rtL180M (28)
15	D	Wt	rtM204V
			rtL180M (32)
16	D	Wt	rtM204V
			rtL180M (19)
17	D	Wt	rtM204V
			rtL180M (21)
18	D	Wt	rtM204I (12)
Primary non-response
11	D	Wt	rtM204I (9)
12	D	Wt	rtM204V (11)
13	D	Wt	rtM204I (11)
14	D	Wt	rtM204I (9)
15	D	Wt	rtM204I (12)

Treatment group:

¹LAM:100;

²LAM:200.